As the field moves beyond melanoma, the need for optimized efficacy and safety is forcing a rethink of manufacturing strategies and delivery strategies.

This workshop addresses the growing recognition that current TIL strategies involve bulk TIL expansion, diluting tumor reactive potential and requiring high dose IL-2 for efficacy.

Key questions addressed in this workshop:

• Which tumor-infiltrating lymphocyte subsets are truly reactive rather than expanded bystanders?
• Do selection approaches such as PD-1 or neoantigen targeting enrich potency or accelerate exhaustion?

• How can next-generation approaches optimize safety vs. efficacy?